Cell survival and bone
Lab research
HNG, a modified humanin analogue, mitigated early growth suppression and cortical bone changes in glucocorticoid-treated B10.mdx mice. This does not establish benefits of native humanin in people.1
Longevity
Humanin
Mitochondria-associated research peptide
No FDA-approved product identified for this exact research entry in the targeted review.
What does it do?
Molecular information
2Amino-acid sequence
- Met
- Ala
- Pro
- Arg
- Gly
- Phe
- Ser
- Cys
- Leu
- Leu
- Leu
- Leu
- Thr
- Ser
- Glu
- Ile
- Asp
- Leu
- Pro
- Val
- Lys
- Arg
- Arg
- Ala
24 residues · N → C2
Length24 amino acids
Molecular weight · Da2687.2 Da
Molecular formulaC119H204N34O32S22
M–A–P–R–G–F–S–C–L–L–L–L–T–S–E–I–D–L–P–V–K–R–R–AHumanin parent sequence; HNG is a different analogue.
Native humanin, not HNG or an acetate salt.
Pharmacokinetics
Unverified reference estimateNot independently confirmed
Reference half-life15 min – 30 min18
Route / formulationSource page: Injectable. Exact PK route not verified.
This value is reported by a secondary reference. The stated attribution has not been independently verified as a route- and formulation-matched human PK measurement.
50%–70.7%of reference level
Illustrative scenario using an unverified reference estimate. Shading shows the reported half-life range. No midpoint is assumed.
About 3% remaining after 1.25 h–2.5 h
Five half-lives in this estimated model. This is not a prediction of when effects stop.
About this estimate
Population: Not established by the reference estimate
Source’s stated attribution: Chin et al. 2013 (PMID 23836030)
Source’s reported peak time: 10 min. This has not been independently confirmed and is not used in the elimination curve.
100 × 2−time / half-life. Time zero is a reference level, not the moment of administration. Absorption, repeated dosing, metabolites and clinical effects are not modeled. Five half-lives leaves 3.125%, not zero. This curve cannot determine a dosing interval.
What to expect
Study outcomes
Analogue findings in a mouse disease model
Analogue, species and treatment context materially limit translation to research humanin.1
Doses & schedules
Route
Scroll to compare all columns →
| Route | Dose | Frequency | Goal / evidence | Duration | References |
|---|---|---|---|---|---|
| SubQSubQ (abdomen or thigh) | 100 mcg SubQStarting dose | 2-3x weekly | Conservative startReference report | 4-8 weeks with 4-week break between cycles | 19 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Interaction categories are source hypotheses; animal tolerability cannot establish human safety. Source tabs Injectable | |||||
| SubQSubQ (community anecdotal protocol; no peer-reviewed human dose-finding study exists) | 200-500 mcg SubQ | 3x weekly | Standard ProtocolReference report | 4-8 weeks with 4-week break between cycles | 19 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Interaction categories are source hypotheses; animal tolerability cannot establish human safety. Source tabs Injectable | |||||
| OralOral (limited data; injectable route preferred for research-grade dosing) | No validated dose for oral route; commercial oral products exist without peer-reviewed PK support | Per specific product label if using a commercial oral formulation | Research ProtocolReference report | Not specified | 19 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Interaction categories are source hypotheses; animal tolerability cannot establish human safety. Source tabs Oral | |||||
No protocols match these filters.
Study and label doses retain their study context. Reference reports are unvalidated practices, not personal treatment instructions. Ranges remain ranges; escalation stages are labeled.
Reported use periods and breaks. These do not establish a safe cycle or prove that breaks prevent tolerance.
Injectable
- Use period
- 4-8 weeks with 4-week break between cycles
- Break
- 4 weeks
Reported timing
No time-of-day requirement established; morning is conventional
Oral
- Use period
- Not established
- Break
- Not established
Reported timing
Not established
Animal and cell protocols 2
Laboratory exposures cannot establish a human dose.
Route
Scroll to compare all columns →
| Route | Dose | Frequency | Goal / evidence | Duration | References |
|---|---|---|---|---|---|
| OtherIntraperitoneal | HNG analogue 1 mg/kg | Daily | Bone effects during glucocorticoid treatmentYoung male B10.mdx miceAnimals | Four weeks | 1 |
Population Young male B10.mdx mice Context HNG, not native humanin; no human dose conversion. | |||||
| IVIntravenous | 1-10 mg/kg IP or IV | Daily in acute rodent neuroprotection models | Research ProtocolReference report | 4-8 weeks with 4-week break between cycles | 19 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Interaction categories are source hypotheses; animal tolerability cannot establish human safety. Source route wording IP or IV (animal models only; representative of published preclinical dosing) Source tabs Injectable | |||||
| OtherIntraperitoneal | 1-10 mg/kg IP or IV | Daily in acute rodent neuroprotection models | Research ProtocolReference report | 4-8 weeks with 4-week break between cycles | 19 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Interaction categories are source hypotheses; animal tolerability cannot establish human safety. Source route wording IP or IV (animal models only; representative of published preclinical dosing) Source tabs Injectable | |||||
No protocols match these filters.
Side effects & safety
Evidence limitation
This experiment did not establish human safety or long-term effects.
1Evidence limitation
Native humanin and Gly14-humanin are distinct molecules; potency and dosing are not interchangeable.
1Unknown human safety
No validated human protocol; oral absorption and brain access unestablished.
Growth/glucose effects
Cancer-treatment interference and IGF-1 binding concerns; possible additive hypoglycemia.
Stop symptoms
Allergy, low glucose, severe injection reactions or new neurological symptoms; oral GI intolerance.
Not a complete safety screen. Discuss health decisions with a qualified clinician.
Combinations & interactions
8 entriesCheck cautions and reported pairings. A compatibility claim does not establish that a combination is safe.
IGF-1 / IGF-1 LR3
Caution reportedIGFBP-3 effects uncertain.19
Reference report · Pep-Pedia label: Monitor CombinationChemotherapy agents
Caution reportedAnti-apoptotic interference concern.19
Reference report · Pep-Pedia label: Monitor CombinationMOTS-c
Unverified pairingTheoretical mitochondrial complement.19
Reference report · Pep-Pedia label: SynergisticSS-31
Unverified pairingMechanistic complement, not trial proof.19
Reference report · Pep-Pedia label: SynergisticNAD+
Unverified pairingNo established combination safety.19
Reference report · Pep-Pedia label: CompatibleEpitalon
Unverified pairingUntested pairing.19
Reference report · Pep-Pedia label: CompatibleInsulin/insulin sensitizers
Unverified pairingPossible additive glucose lowering.19
Reference report · Pep-Pedia label: CompatibleOther medicines or peptides
Not establishedNo exact-product human interaction study was verified; lack of evidence is not evidence of safety.3
Research contextNo matching interactions. Try another name or filter.
Reconstitution
No product-specific preparation or stability instruction was verified. A dilution calculation does not establish suitability for injection.3
Reference preparation details
Reported handling information, not a validated formulation or instruction to prepare an injectable product.
Injectable
The source gives a 1 mg vial example.
- Solvents mentioned
- Bacteriostatic water
- Reported parameters
- 1–2 mL gives 1–0.5 mg/mL. · Reported storage: 2–8°C for 21 days.
The source describes gentle mixing and avoiding vigorous shaking.
Oral
Pep-Pedia reports no peer-reviewed oral preparation or administration protocol.
A commercial oral product claim does not establish a validated formulation.
Appearance & documentation
Appearance and a purity certificate cannot establish sterility, identity, or suitability for injection.
Reported appearanceWhite Lyophilized PowderReported appearanceClear Solution After ReconstitutionReported appearanceCertificate of Analysis with Sequence VerificationReported variationConfirm Isoform on Label (HN vs. HNG)Reported variationCold-Chain ShippingReported concernDo Not Inject Cloudy or Discolored Solutions
19Available forms
No verified packaging examples included.
Packaging examples, not a market survey. Approved and research products are not interchangeable.
Storage after mixing
Reconstituted research vials
Pep-Pedia reports these handling limits after mixing. They are not validated stability or sterility limits for your vial.
Storage notes
19Lyophilized: room temperature short-term or freezer. Reconstituted: 2-8°C, use within 21 days.
Room temperature per specific product label
Storage depends on the formulation, diluent, container, and handling. Follow the specific product label or pharmacist’s instructions.
Evidence limits
View findings →Analogue, species and treatment context materially limit translation to research humanin.1
2 distinct primary sources or abstracts checked. Evidence may concern a parent compound, individual blend ingredient, animal, or cell model; it does not necessarily establish a benefit for this exact product.
Evidence definitions →Research findings
PreclinicalSource context
Interaction categories are source hypotheses; animal tolerability cannot establish human safety.
Compound identity & other names
Humanin and modified analogues are studied in cellular stress, metabolism and aging models. Animal interventions and human biomarker associations do not establish benefits from administering humanin to people.
No FDA-approved product identified for this exact research entry in the targeted review.
MAPRGFSCLLLLTSEIDLPVKRRA2
Pep-Pedia identity record
24 amino acids · ~2.8 kDa
MAPRGFSCLLLLTSEIDLPVKRRA (Met-Ala-Pro-Arg-Gly-Phe-Ser-Cys-Leu-Leu-Leu-Leu-Thr-Ser-Glu-Ile-Asp-Leu-Pro-Val-Lys)Reference description; checked chemical identity takes precedence when available.19
How it may work
FPR2 and gp130-complex signaling, IGFBP-3/Bax interactions and anti-apoptotic pathways; HNG analog findings are not automatically native-Humanin findings.19
Analogue findings in a mouse disease model
HNG, a modified humanin analogue, mitigated early growth suppression and cortical bone changes in glucocorticoid-treated B10.mdx mice. This does not establish benefits of native humanin in people.
1Research areas and evidence gaps
Cell survival and bone research. HNG, a modified humanin analogue, mitigated early growth suppression and cortical bone changes in glucocorticoid-treated B10.mdx mice. This does not establish benefits of native humanin in people.1
- Analogue, species and treatment context materially limit translation to research humanin.
- A product-specific research-vial quantity was not independently verified in this review.
Additional uses listed by Pep-Pedia
Brain and synapses. Amyloid/ischemia survival models; no demonstrated human cognitive outcome.19
Cardiac protection. Animal ischemia–reperfusion research.19
Metabolism and pancreatic cells. Insulin/glucose and beta-cell models.19
Aging and reproductive protection. Longevity associations and animal germ-cell preservation.19
Community reports Unvalidated
Pep-Pedia discusses cellular stress and aging research.3
Editorial summary, not a measured community survey, clinical protocol or recommendation.
Search coverage and review status
Added a 2026 HNG mouse bone study. The Gly14 analogue is distinguished from native humanin.
- Checked
- 2026-10-12
- Search
- "humanin" "2026" study; humanin bone HNG 2026
- Catalog
- Pep-Pedia ↗ · 14 listed references retained
- Targeted search and selected primary-source checks, not an exhaustive systematic review.
- Preserved bibliography entries marked unreviewed have not had their findings independently verified.
AI-prepared summaries. Independent medical editorial review is pending.
Community poll Results availability
The source explicitly reported no responses when checked.
References
Original sources and review status. Open a reference to read its summary.
1Humanin improves bone health in a glucocorticoid-treated mouse model of Duchenne muscular dystrophyPrimary source checked
AI-PREPARED SUMMARY
The Gly14 analogue HNG reduced some glucocorticoid-related bone changes in mdx mice. Results varied with mouse strain and regimen; no patients received humanin.
Analogue findings in a mouse disease model
HNG, a modified humanin analogue, mitigated early growth suppression and cortical bone changes in glucocorticoid-treated B10.mdx mice. This does not establish benefits of native humanin in people.
Additional research · Checked 2026-10-12
2PubChem: HumaninPrimary source checked
AI-PREPARED SUMMARY
Chemical identity for native 24-amino-acid humanin, distinct from the Gly14 analogue.
Additional research · Checked 2026-10-12
3Pep-Pedia: HumaninCommunity source checked
AI-PREPARED SUMMARY
Secondary editorial profile and reported practices; not clinical validation.
4Discovery: Neuroprotection Against Alzheimer Disease Genes (2001, PNAS)Pep-Pedia report · Primary source not checked
AI-PREPARED SUMMARY
Pep-Pedia reports: Humanin reduced neuronal death in amyloid and familial-Alzheimer gene models; a related mechanistic paper implicated Bax binding.
Reported population / model
Human cDNA
Reported study details
Humanin peptide · In vitro / mouse · Suppressed Abeta and FAD gene-induced apoptosis
Reported by Pep-Pedia; the linked publication, design, doses and result have not been independently verified here.
Read the Pep-Pedia report ↗Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12
5Humanin as a Longevity Regulator (Yen et al. 2020)Pep-Pedia report · Primary source not checked
AI-PREPARED SUMMARY
Pep-Pedia reports: Higher Humanin was associated with longevity-family phenotypes; observational human associations and mouse interventions do not prove longer human life.
Reported population / model
Human + Mouse
Reported study details
Observational + Interventional · Centenarian cohort · 3x higher Humanin in long-lived families; lifespan effects in mice
Reported by Pep-Pedia; the linked publication, design, doses and result have not been independently verified here.
Read the Pep-Pedia report ↗Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12
6Cardiac Ischemia-Reperfusion Protection (2010)Pep-Pedia report · Primary source not checked
AI-PREPARED SUMMARY
Pep-Pedia reports: Acute Humanin exposure reduced mouse infarct size and cardiac-cell death during reperfusion experiments.
Reported population / model
Mouse
Reported study details
Humanin IV acute dose · Cardiac I/R model · Reduced infarct size, improved cardiac function
Reported by Pep-Pedia; the linked publication, design, doses and result have not been independently verified here.
Read the Pep-Pedia report ↗Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12
7Testicular Germ Cell Protection from Chemotherapy (2014)Pep-Pedia report · Primary source not checked
AI-PREPARED SUMMARY
Pep-Pedia reports: The HNG analogue protected mouse testicular germ cells under chemotherapy; this is analogue-specific animal evidence.
Reported population / model
Mouse
Reported study details
HNG analog IP · Chemotherapy-induced gonadotoxicity model · Preserved spermatogenesis
Reported by Pep-Pedia; the linked publication, design, doses and result have not been independently verified here.
Read the Pep-Pedia report ↗Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12
8Insulin Sensitivity and Metabolic Protection (2018)Pep-Pedia report · Primary source not checked
AI-PREPARED SUMMARY
Pep-Pedia reports: Mouse experiments reported improved insulin sensitivity and less visceral fat; accompanying human data were observational associations with circulating Humanin.
Reported population / model
Mouse
Reported study details
Humanin IP · HFD and aging models · Improved insulin sensitivity, reduced visceral fat
Reported by Pep-Pedia; the linked publication, design, doses and result have not been independently verified here.
Read the Pep-Pedia report ↗Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12
9Humanin Serum Decline With AgePep-Pedia report · Primary source not checked
AI-PREPARED SUMMARY
Pep-Pedia reports: The source describes lower circulating Humanin with older age; this association does not show supplementation reverses aging.
Reported population / model
Human
Reported study details
Observational · Cross-sectional aging cohort · Humanin declines with age
Reported by Pep-Pedia; the linked publication, design, doses and result have not been independently verified here.
Read the Pep-Pedia report ↗Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12
10A rescue factor abolishing neuronal cell death by familial Alzheimer’s disease genes and AbetaPep-Pedia report · Primary source not checked
AI-PREPARED SUMMARY
Pep-Pedia reports: Humanin reduced neuronal death in amyloid and familial-Alzheimer gene models; a related mechanistic paper implicated Bax binding.
Reported population / model
Human cDNA
Reported study details
Humanin peptide · In vitro / mouse · Suppressed Abeta and FAD gene-induced apoptosis
Reported by Pep-Pedia; the linked publication, design, doses and result have not been independently verified here.
Read the Pep-Pedia report ↗Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12
11Humanin peptide suppresses apoptosis by interfering with Bax activationLinked reference · Not independently reviewed
REFERENCE NOTE
Reference retained from Pep-Pedia’s bibliography; findings and bibliographic accuracy have not been independently verified.
Pep-Pedia bibliography · Checked 2026-10-12
12Humanin: a novel central regulator of peripheral insulin actionLinked reference · Not independently reviewed
REFERENCE NOTE
Reference retained from Pep-Pedia’s bibliography; findings and bibliographic accuracy have not been independently verified.
Pep-Pedia bibliography · Checked 2026-10-12
13Pharmacokinetics and tissue distribution of Humanin and analogues in male rodentsLinked reference · Not independently reviewed
REFERENCE NOTE
Reference retained from Pep-Pedia’s bibliography; findings and bibliographic accuracy have not been independently verified.
Pep-Pedia bibliography · Checked 2026-10-12
14Humanin activates ERK1/2, AKT and STAT3 signaling with age-dependent differences in hippocampusLinked reference · Not independently reviewed
REFERENCE NOTE
Reference retained from Pep-Pedia’s bibliography; findings and bibliographic accuracy have not been independently verified.
Pep-Pedia bibliography · Checked 2026-10-12
15The mitochondrial derived peptide humanin is a regulator of lifespan and healthspanPep-Pedia report · Primary source not checked
AI-PREPARED SUMMARY
Pep-Pedia reports: Higher Humanin was associated with longevity-family phenotypes; observational human associations and mouse interventions do not prove longer human life.
Reported population / model
Human + Mouse
Reported study details
Observational + Interventional · Centenarian cohort · 3x higher Humanin in long-lived families; lifespan effects in mice
Reported by Pep-Pedia; the linked publication, design, doses and result have not been independently verified here.
Read the Pep-Pedia report ↗Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12
16Humanin and diabetes mellitus: a review of in vitro and in vivo studiesLinked reference · Not independently reviewed
REFERENCE NOTE
Reference retained from Pep-Pedia’s bibliography; findings and bibliographic accuracy have not been independently verified.
Pep-Pedia bibliography · Checked 2026-10-12
17Neuroprotective Action of Humanin and Humanin Analogues: Research Findings and PerspectivesLinked reference · Not independently reviewed
REFERENCE NOTE
Reference retained from Pep-Pedia’s bibliography; findings and bibliographic accuracy have not been independently verified.
Pep-Pedia bibliography · Checked 2026-10-12
18Pep-Pedia: Humanin — reported pharmacokineticsReference estimate; not independently verified human PKCommunity source checked
AI-PREPARED SUMMARY
Lists a half-life of 15 min – 30 min and a peak time of 10 min. Stated attribution: Chin et al. 2013 (PMID 23836030). This value is reported by a secondary reference. The stated attribution has not been independently verified as a route- and formulation-matched human PK measurement. Five half-lives is not complete clearance, and the source’s “cleared” value is not used as a measured endpoint.
Secondary reference page checked; the underlying quantitative claim is not independently confirmed. · Checked 2026-10-12
19Pep-Pedia: Humanin — route-specific referenceReference page checked; underlying claims require separate verification.Community source checked
AI-PREPARED SUMMARY
Source page checked across available routes. Protocols, cycles, storage, mechanisms and pairing claims are secondary reports; checking the page does not independently validate those claims. Original concise summaries are used here.
Content coverage audit · Checked 2026-10-12